Trials / No Longer Available
No Longer AvailableNCT01613053
Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Continuation of drug supply in Chinese patients after CAMN107DBR01study termination.
Detailed description
Five patients who are on treatment of imatinib and deriving clinical benefit after CAMN107DBR01 study termination and written informed consent obtained will enter the trial, all five patients will receive Glivec (8oomg per day) treatment until tumor progression \[by RECIST guidelines, version 1.0\], unacceptable toxicity, death or withdrawal of consent.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glivec | 800 mg per day |
Timeline
- First posted
- 2012-06-06
- Last updated
- 2015-04-24
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01613053. Inclusion in this directory is not an endorsement.